Jefferson College of Public Health Founding Dean Emeritus David Nash says testing will be key as the U.S. looks to return to normalcy after the initial wave of COVID-19. "I don't know if anybody has the right answers here," he said. "Testing, more testing and even more testing. That is the key […]
Report: Remdesivir Trials Posting Promising Results
Gilead's COVID-19 treatment, remdesivir, is showing some promise in clinical trials which have seen swift recoveries of symptoms in severe COVID-19 patients, according to a STAT report. According to the report, Gilead's two Phase 3 trials involved 125 patients, 113 of whom were severe cases. The […]
Frakt, Stevens Seek Input on Planned Survey on Post-Pandemic Predictions
Rob Stevens and Austin Frakt are developing a survey on predictions for post-pandemic behavior and trends, and have asked for input as they work to develop questions. Read more on The Incidental Economist by clicking here. […]
NHC Launches Online Value Classroom
The National Health Council (NHC) recently announced the launch of the Value Classroom, a new online learning platform aimed at helping patients find their voice in value discussions. "These resources are intended to help patients and patient advocates engage in discussions on and the assessment […]
HealthCore’s Beachler, Lanes Talk Bolstering RWE with New Tech
In the latest tHEORetically Speaking blog post, HealthCore's Daniel Beachler, Safety & Epidemiology associate director, and Stephen Lanes, Safety & Epidemiology principal epidemiologist, outline how innovative technologies could be used to bolster real-world evidence in precision […]
ICER Names Venable VP of Patient Engagement
The Institute for Clinical and Economic Review (ICER) announced the appointment of Yvette Venable as its first-ever vice president of patient engagement. ICER in a press release says Venable brings to the table 20-plus years of experience in patient advocacy, health policy and biopharma […]
Health Care Industry Leveraging RWD to Combat COVID-19
The health care industry is looking to better leverage real-world data in the midst of the COVID-19 pandemic as it looks to get ahead of the virus, according to a Health IT Analytics report. According to the report, leaders are looking to a range of data sources to glean key insights, including […]
Program Looks to Address Gaps in COVID-19 Data
The Robert Wood Johnson Foundation's Health Data for Action program is supporting a collaboration between Health Care Cost Institute (HCCI), CareJourney and the Berkeley Research Group in an effort to fill in the gaps in COVID-19 data. AcademyHealth manages the Health Data for Action […]
Clayton-Welch: Quality, Speed, Compliance Key in Dynamic Market Access Landscape
In the second of her five-part series on digital transformation in market access, HealthEconomics.Com© LLC CEO Patti Peeples sits down with PRMA Consulting's Sophie Clayton-Welch to discuss three ways that new technology is helping market access professionals gain cost-effective, real-time payer […]
Prime Therapeutics Initiative Aims to Help Plan Sponsors Pay for Gene Therapies
The new PreserveRx program from Prime Therapeutics looks to help plan sponsors deal with high-cost gene therapies, Fierce Healthcare reports. According to the report, members of the new program will pay a monthly fee in order to be protected from the crippling costs of expensive drugs like […]
HealthEconomics.Com, Scientist.Com Announce HEOR, RWE Partnership
HealthEconomics.Com© LLC and Scientist.Com are partnering to streamline HEOR and real-world evidence sourcing in the global HEOR and RWE community and pharma market with the new HEOR & RWE Marketplace. The marketplace offers stakeholders an online platform to both evaluate and purchase HEOR […]
Blog Post Highlights Impact Coronavirus Could Have on New Drug Launches
A recent blog post on Tribeca Knowledge outlines some of the key challenges pharmaceutical companies face regarding drug launches in the midst of the COVID-19 pandemic. Drug launches outside the COVID-19 arena "are under threat of delay, postponement, dilution or worse," the author, Andre Moa, […]
Shkreli Seeks Furlough to Research Potential COVID-19 Treatments
Disgraced biotech entrepreneur Martin Shkreli is requesting a 3-month furlough to research potential treatments for COVID-19, STAT reports. In a scientific paper published online, Shkreli lays out how he could contribute to the pandemic response. "As a successful two-time biopharma […]
ISPOR 2020 Goes Virtual
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is moving its annual meeting into the virtual space in response to the COVID-19 pandemic, the society announced Monday, April 6. According to the announcement, the online event will kick off May 18. ISPOR says the […]
AMCP to Supreme Court: Ruling Against PCMA Could Raise Health Costs
The Academy of Managed Care Pharmacy (AMCP) in an amicus brief filed in the Supreme Court tells the court ruling against the Pharmaceutical Care Management Association (PCMA) in Rutledge v. PCMA could have a negative impact on costs and patient outcomes. According to a press release, the case […]
MSK’s Bach Talks High-Value Drug Development
Memorial Sloan Kettering Cancer Center's Dr. Peter Bach in a recent interview with Liam Bendicksen discusses ways to optimize high-value drug development. Bach said while it's a complex effort, the goal is to pay as little as possible to pharmaceutical companies to "incentivize high-value […]
ISPOR Task Force Publishes New Good Practices Reports
The International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) Value of Information Analysis Emerging Good Practices Task Force has had two good practices reports published in Value in Health since February. The following are the published reports: Value of Information […]
Calculating Costs, Benefits of Lockdowns
How do economists calculate the value of preventing COVID-19 deaths? The authors of a recent article published on Forbes outline the methods economists use to project the potential impact on costs. While putting a dollar amount on a human life may make some "uncomfortable," the authors write, […]
PRMA’s Chadwick Talks Digital Tech’s Impact on Market Access
PRMA Consulting HTA Manager Claire Chadwick outlines how digital technology is changing the face of the market access landscape in the latest tHEORetically Speaking blog post. HealthEconomics.Com LLC CEO and HE Institute Principal Researcher Patti Peeples conducted the interview. Chadwick […]
Article Outlines How Health Plans Utilize RWE for Specialty Drug Coverage
Health plans' use of real-world evidence for specialty drug coverage decisions is generally varied in terms of the number and type of studies cited, according to a recent article published by Wiley. The authors, Ari Panzer et al., used data from the Tufts Medical Center Specialty Drug Evidence […]
Waystar: Poor Price Transparency is ‘Single Biggest Issue’ in Patient’s Financial Experience
In a sponsored article on HealthLeaders Media, Waystar outlines the patient's need for more "financial clarity" during their health care journey. Waystar points to a 2019 published in JAMA which suggests it's becoming more likely for patients to be billed by an out-of-network provider despite […]
eyeforpharma Philadelphia Pivots to Virtual Event
In response to the COVID-19 outbreak, eyeforpharma is transitioning its eyeforpharma Philadelphia conference to a free, online event. The 4-day virtual conference is set to kick off April 14, and will feature more than 70 sessions and more than 70 speakers. "The Covid-19 coronavirus has […]
NICE Publishes COVID-19 Guidelines
The National Institute for Health and Care Excellence (NICE) on March 21 published a new set of guidelines that address the management of patients with COVID-19, and those without. NICE says the guidelines aim to bolster patient safety, as well as facilitate the "best use of NHS resources and […]
Webinar – Faster to Market: Transforming HEOR & RWE Using Virtual Sourcing
Wish you could get HEOR & RWE projects started faster, cheaper, & using the most optimal vendor? Do you want to connect with new buyers in this age of reduced face-to-face business development? Some of the biggest challenges in HEOR & RWE are long contracting time, lack of RFI […]
Blog Post Mulls Indirect Benefits in Value Assessments
A recent blog post published on Health Affairs highlights some key reasons why indirect benefits should be factored into value assessments. The authors, National Pharmaceutical Council Vice President of Research Michael Ciarametaro et al., suggest indirect benefits in value assessments have "the […]
Predictions for RWE in 2020
A recent article published on PharmaTimes looks at what the future may hold for real-world evidence amid rising interest in the pharmaceutical industry. The author, Verantos CEO Dan Riskin, widespread efforts to establish robust RWE "provides a significant opportunity to refine the standard of […]
Lin: Clinical Practice Guidelines Not Broken
Family physician and Common Sense Family Doctor blogger Kenneth Lin in a recent post published on MedPage Today writes that while "clinical practice guidelines have problems, they're not broken." Lin was referencing the title of a Health Affairs blog post, "Fixing Clinical Practice Guidelines," […]
ICER Indefinitely Postpones Public Meetings, Expands Assessment Timelines
In response to the COVID-19 pandemic, the Institute for Clinical and Economic Review (ICER) announced it would indefinitely postpone several public meetings and push out the timelines for assessments. The following details were provided in a press release sent out Wednesday morning: Sickle […]
AMCP Cancels Annual Meeting
The Academy of Managed Care Pharmacy (AMCP) has canceled its annual meeting, which was set to begin April 21, saying that holding the meeting amid the COVID-19 outbreak has "become impermissible." "We deeply appreciate your patience as AMCP leaders and staff have monitored and responded to this […]
Pfizer Offers Its Resources in Fight Against Coronavirus
Pfizer is entering the fight against coronavirus after announcing it would offer its resources for wider use, FiercePharma reports. The drugmaker is also calling on other drugmakers to collaborate, according to the report. "Pfizer calls on all members of the innovation ecosystem—from large […]
